MX2019008032A - Combinaciones de cabozantinib y atezolizumab para tratar cancer. - Google Patents
Combinaciones de cabozantinib y atezolizumab para tratar cancer.Info
- Publication number
- MX2019008032A MX2019008032A MX2019008032A MX2019008032A MX2019008032A MX 2019008032 A MX2019008032 A MX 2019008032A MX 2019008032 A MX2019008032 A MX 2019008032A MX 2019008032 A MX2019008032 A MX 2019008032A MX 2019008032 A MX2019008032 A MX 2019008032A
- Authority
- MX
- Mexico
- Prior art keywords
- cabozantinib
- atezolizumab
- combinations
- treat cancer
- advanced
- Prior art date
Links
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 title abstract 2
- 229960003852 atezolizumab Drugs 0.000 title abstract 2
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 title abstract 2
- 229960001292 cabozantinib Drugs 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 208000006265 Renal cell carcinoma Diseases 0.000 abstract 1
- 208000037843 metastatic solid tumor Diseases 0.000 abstract 1
- 206010044412 transitional cell carcinoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Esta invención se refiere a la combinación de cabozantinib y atezolizumab para tratar tumores sólidos metastásicos o localmente avanzados, particularmente, carcinoma de células renales o cáncer urotelial avanzado.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762448869P | 2017-01-20 | 2017-01-20 | |
US201762458447P | 2017-02-13 | 2017-02-13 | |
PCT/US2018/014523 WO2018136796A1 (en) | 2017-01-20 | 2018-01-19 | Combinations of cabozantinib and atezolizumab to treat cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019008032A true MX2019008032A (es) | 2019-12-16 |
Family
ID=61569414
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019008032A MX2019008032A (es) | 2017-01-20 | 2018-01-19 | Combinaciones de cabozantinib y atezolizumab para tratar cancer. |
MX2022001718A MX2022001718A (es) | 2017-01-20 | 2019-07-03 | Combinaciones de cabozantinib y atezolizumab para tratar cancer. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022001718A MX2022001718A (es) | 2017-01-20 | 2019-07-03 | Combinaciones de cabozantinib y atezolizumab para tratar cancer. |
Country Status (13)
Country | Link |
---|---|
US (2) | US11198731B2 (es) |
EP (1) | EP3570840A1 (es) |
JP (3) | JP7222895B2 (es) |
KR (2) | KR20230169458A (es) |
CN (4) | CN117205313A (es) |
AU (1) | AU2018210397B2 (es) |
BR (1) | BR112019015011A2 (es) |
CA (1) | CA3049452A1 (es) |
IL (1) | IL268138B (es) |
MA (1) | MA47310A (es) |
MX (2) | MX2019008032A (es) |
UA (1) | UA126970C2 (es) |
WO (1) | WO2018136796A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3521291A1 (en) | 2010-05-20 | 2019-08-07 | Array Biopharma, Inc. | Macrocyclic compounds as trk kinase inhibitors |
WO2016019285A1 (en) | 2014-07-31 | 2016-02-04 | Exelixis, Inc. | Method of preparing fluorine-18 labeled cabozantinib and its analogs |
MA44672A (fr) | 2016-04-15 | 2019-02-20 | Exelixis Inc | Procédé de traitement du cancer à cellules rénales à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophény)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate |
EP3571203B1 (en) | 2017-01-18 | 2023-06-07 | Array BioPharma Inc. | Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors |
MA47310A (fr) * | 2017-01-20 | 2019-11-27 | Exelixis Inc | Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
CA3087578C (en) | 2018-01-18 | 2023-08-08 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
CN111615514B (zh) | 2018-01-18 | 2022-10-11 | 奥瑞生物药品公司 | 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物 |
TWI802635B (zh) | 2018-01-18 | 2023-05-21 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物 |
CN117820226A (zh) | 2018-01-26 | 2024-04-05 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
JP2021536489A (ja) * | 2018-09-05 | 2021-12-27 | ベントリア、バイオサイエンス、インコーポレイテッドVentria Bioscience Inc. | 免疫グロブリンa製剤 |
ES2922314T3 (es) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Compuestos heterocíclicos condensados como inhibidores de cinasa RET |
TW202207940A (zh) * | 2020-04-14 | 2022-03-01 | 美商健生生物科技公司 | 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物 |
PE20231369A1 (es) * | 2020-07-31 | 2023-09-07 | Exelixis Inc | Combinaciones para el tratamiento del cancer |
KR20230158057A (ko) * | 2021-03-19 | 2023-11-17 | 머크 샤프 앤드 돔 엘엘씨 | 항-ilt3 항체를 사용하여 암을 치료하는 방법 |
US11620580B2 (en) * | 2021-04-01 | 2023-04-04 | Banjo Health Inc. | Methods and systems for probabilistic filtering of candidate intervention representations |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2371383T3 (es) | 2003-09-26 | 2011-12-30 | Exelixis, Inc. | N-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinolin-4-il}oxi)fenil]-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida para el tratamiento del cáncer. |
WO2008083319A1 (en) | 2006-12-29 | 2008-07-10 | Il Yang Pharmaceutical Company, Ltd. | Solid state forms of enantiopure ilaprazole |
HRP20240240T1 (hr) | 2008-12-09 | 2024-04-26 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
TW202241853A (zh) | 2009-01-16 | 2022-11-01 | 美商艾克塞里克斯公司 | 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途 |
MX336741B (es) | 2010-07-16 | 2016-01-29 | Exelixis Inc | Composiciones farmaceuticas de moduladores de c-met. |
AU2014248001A1 (en) * | 2013-04-04 | 2015-11-19 | Exelixis, Inc. | Drug combinations to treat cancer |
MX2021001583A (es) * | 2014-02-14 | 2023-02-08 | Exelixis Inc | Formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ] fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboración y métodos de uso. |
MA44672A (fr) | 2016-04-15 | 2019-02-20 | Exelixis Inc | Procédé de traitement du cancer à cellules rénales à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophény)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate |
CN109475545A (zh) | 2016-04-19 | 2019-03-15 | 埃克塞里艾克西斯公司 | 三阴性乳腺癌治疗方法 |
MA47310A (fr) * | 2017-01-20 | 2019-11-27 | Exelixis Inc | Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer |
-
2018
- 2018-01-19 MA MA047310A patent/MA47310A/fr unknown
- 2018-01-19 US US16/479,143 patent/US11198731B2/en active Active
- 2018-01-19 UA UAA201909420A patent/UA126970C2/uk unknown
- 2018-01-19 JP JP2019539223A patent/JP7222895B2/ja active Active
- 2018-01-19 IL IL268138A patent/IL268138B/en unknown
- 2018-01-19 CN CN202311144074.8A patent/CN117205313A/zh active Pending
- 2018-01-19 CN CN201880013200.7A patent/CN110352057A/zh active Pending
- 2018-01-19 WO PCT/US2018/014523 patent/WO2018136796A1/en active Application Filing
- 2018-01-19 CA CA3049452A patent/CA3049452A1/en active Pending
- 2018-01-19 EP EP18709192.1A patent/EP3570840A1/en active Pending
- 2018-01-19 CN CN202311144073.3A patent/CN117205312A/zh active Pending
- 2018-01-19 BR BR112019015011A patent/BR112019015011A2/pt active Search and Examination
- 2018-01-19 CN CN202311144084.1A patent/CN117771363A/zh active Pending
- 2018-01-19 KR KR1020237041680A patent/KR20230169458A/ko active Application Filing
- 2018-01-19 KR KR1020197024015A patent/KR102610764B1/ko active IP Right Grant
- 2018-01-19 MX MX2019008032A patent/MX2019008032A/es unknown
- 2018-01-19 AU AU2018210397A patent/AU2018210397B2/en active Active
-
2019
- 2019-07-03 MX MX2022001718A patent/MX2022001718A/es unknown
-
2021
- 2021-11-04 US US17/519,327 patent/US20220056138A1/en active Pending
-
2022
- 2022-06-29 JP JP2022104523A patent/JP2022121594A/ja active Pending
-
2023
- 2023-12-28 JP JP2023222710A patent/JP2024019720A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US11198731B2 (en) | 2021-12-14 |
UA126970C2 (uk) | 2023-03-01 |
US20190352403A1 (en) | 2019-11-21 |
KR20190107103A (ko) | 2019-09-18 |
CN110352057A (zh) | 2019-10-18 |
KR102610764B1 (ko) | 2023-12-07 |
KR20230169458A (ko) | 2023-12-15 |
MA47310A (fr) | 2019-11-27 |
AU2018210397A1 (en) | 2019-07-25 |
JP2022121594A (ja) | 2022-08-19 |
CN117205312A (zh) | 2023-12-12 |
US20220056138A1 (en) | 2022-02-24 |
MX2022001718A (es) | 2022-03-11 |
IL268138A (en) | 2019-09-26 |
IL268138B (en) | 2022-08-01 |
JP2020514311A (ja) | 2020-05-21 |
AU2018210397B2 (en) | 2024-02-29 |
JP2024019720A (ja) | 2024-02-09 |
CA3049452A1 (en) | 2018-07-26 |
WO2018136796A1 (en) | 2018-07-26 |
EP3570840A1 (en) | 2019-11-27 |
BR112019015011A2 (pt) | 2020-04-28 |
CN117205313A (zh) | 2023-12-12 |
CN117771363A (zh) | 2024-03-29 |
JP7222895B2 (ja) | 2023-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022001718A (es) | Combinaciones de cabozantinib y atezolizumab para tratar cancer. | |
MX2019007030A (es) | Composiciones y metodos para el tratamiento del cancer. | |
PH12019502875A1 (en) | Antibody molecules to cd73 and uses thereof | |
MX2021000710A (es) | Composiciones que comprenden cepas bacterianas. | |
PH12017501999A1 (en) | K-ras modulators | |
ZA201905902B (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
MX2016007282A (es) | Modulador del receptor de estrogenos para el tratamiento de cancer de mama positivo al receptor de estrogenos localmente avanzado o metastasico. | |
AU2018265888A1 (en) | Use of anti-B7H3 antibodies for treating cancer in the central nervous system | |
MX2016006726A (es) | Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer. | |
EP3134115A4 (en) | Methods and compositions for treating metastatic breast cancer and other cancers in the brain | |
WO2014164704A3 (en) | Compounds and compositions for the treatment of cancer | |
TW201613647A (en) | Compounds and compositions for treating HER2 positive tumors | |
MX2018008427A (es) | Combinaciones anti-cd20 para tratar tumores. | |
PH12018500869A1 (en) | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment | |
MX2018000267A (es) | Combinacion de inhibidores de histona desacetilasa y anticuerpo de ligando 1 de anti-muerte celular programada para el tratamiento de cancer. | |
MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
MX2016015163A (es) | Biomarcadores mit y metodos para su uso. | |
MX2020006297A (es) | Variantes de cd19. | |
MX2020003219A (es) | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. | |
BR112017022022A8 (pt) | Arenavírus para uso no tratamento e/ou prevenção de tumores e método para a produção de arenavírus com propriedades de regressão de tumor (aprimoradas) | |
EP3566705A4 (en) | COMPOSITION FOR THE PREVENTION OR TREATMENT OF METASTATIC OVARIAN CANCER, ENDOMETRIC CANCER OR BREAST CANCER | |
MX2019012136A (es) | Compuestos de union al receptor de la hormona antimulleriana tipo ii (amhrii) para prevenir o tratar canceres de pulmon. | |
MX2019003755A (es) | Regimen de dosificacion de avelumab para el tratamiento de cancer. | |
EA201691896A1 (ru) | Соединения и способы их применения | |
EA201990370A1 (ru) | Терапия рака, связанная с crebbp |